- Home | GSK US
Press releases March 13 2026 GSK’s RSV vaccine, AREXVY, approved in US for expanded age indication in adults aged 18–49 years at increased risk February 18 2026 GSK’s AREXVY associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows
- GSK to invest $30 billion in R D and Manufacturing in the United States . . .
GSK plc (LSE NYSE: GSK) today announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years
- Vaccines | GSK US
The vaccines in our portfolio have been helping to protect people from serious disease for well over 100 years, with our Marietta, PA site dedicated to smallpox vaccine production since 1882 Today, our vaccines continue to make an impact for society by tackling some of the world’s most devastating diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and
- Careers | GSK US
Careers We are GSK At GSK, we unite science, technology and talent to get ahead of disease together We aim to positively impact the health of 2 5 billion people by the end of the decade, as a successful, growing company where people can thrive
- Products - GSK US
Unfortunately, we cannot provide comprehensive information about our products here, in compliance with regulations If you are a healthcare professional, you can access more product information on our GSKPro website In the US, if you are a patient and have questions about our medicines, please contact the GSK Response Center
- Contact us - GSK
Disaster response - Contact our US Response Center online if you need help accessing your GSK medicines during a natural disaster Patient Assistance Programs - We are committed to helping patients access our medications, and have a long history of providing a range of programs to help them
- Purpose, strategy and culture - GSK US
Our culture Culture at GSK is something we all own It powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive Our culture of being ambitious for patients, accountable for impact and doing the right thing is the foundation for how, together, we’ll deliver for patients, shareholders and GSK people
- GSK announces extension of US Food and Drug Administration review . . .
GSK plc (LSE NYSE: GSK) today announced the US Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for Blenrep (belantamab mafodotin-blmf) combinations 1 for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy
|